Related Experiment Video
Updated: Mar 5, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation, Second Thoughts?
1HerzZentrum Hirslanden, Zurich, Switzerland.
Insights
As atrial fibrillation (AF) increases with age, stroke risk rises. Left atrial appendage (LAA) occlusion offers an alternative to anticoagulation for preventing strokes in elderly AF patients at high bleeding risk.
Area of Science:
- Cardiology
- Geriatrics
- Vascular Medicine
Background:
- Global life expectancy is increasing, leading to a higher prevalence of atrial fibrillation (AF) and its complications.
- Chronic AF affects 3-5% of individuals over 65, with 30% experiencing stroke, and AF accounts for 20% of all cerebrovascular accidents.
- Oral anticoagulation is standard for stroke prevention in AF, guided by scores like CHADS2.
Purpose of the Study:
- To evaluate left atrial appendage (LAA) occlusion as an alternative to long-term anticoagulation in elderly patients with AF.
- To assess the clinical real-world perspective of LAA occlusion in managing thromboembolic risk.
- To address the challenges of bleeding complications associated with anticoagulation in older populations.
Main Methods:
- Review of clinical data and outcomes for patients undergoing percutaneous LAA occlusion.
- Analysis of stroke incidence and bleeding risk in AF patients treated with LAA occlusion versus anticoagulation.
- Focus on elderly patients with increased bleeding risk.
Main Results:
- Left atrial appendage (LAA) occlusion is presented as a viable alternative to permanent anticoagulation.
- The procedure is highlighted as an attractive option for elderly AF patients facing elevated bleeding risks.
- Real-world clinical perspectives on the efficacy and safety of LAA occlusion are discussed.
Conclusions:
- Left atrial appendage (LAA) occlusion is a promising therapeutic strategy for stroke prevention in atrial fibrillation (AF).
- It offers a valuable alternative for elderly patients who are not suitable candidates for long-term anticoagulation due to bleeding risks.
- Further real-world data supports LAA occlusion as a key intervention in managing AF-related cerebrovascular events.
Abstract:
Life expectancy of the population is steadily increasing world wide. Consequently, the incidence and ultimately the prevalence of atrial fibrillation (AF) and it's sequelae will be rising proportionately. It is estimated that 3-5% of persons above 65 years of age have chronic AF, 30% of which will suffer at least one stroke. On the other hand, chronic AF is responsible for about 20% of all cerebrovascular accidents. Predictors of stroke in AF have been defined by the CHADS2 score, and in these patients, oral anticoagulation has been the cornerstone of thromboembolic disease prevention. Because elderly patients have an increased risk of bleeding complications even under the newer antagonists of Factor Xa and direct Thrombin inhibitors, percutaneous occlusion of the left atrial appendage (LAA) as the main thrombogenic source offers an attractive alternative to permanent anticoagulation. This promising new therapeutic approach is put into clinical real world perspective.
